Halozyme Therapeutics Inc
HALO
ISIN null / Valor 1814799
Halozyme Therapeutics Inc
UMushroom community rating:
About company
Halozyme Therapeutics Inc is a biopharmaceutical company that specializes in developing and commercializing novel drug delivery technologies. With over three decades of experience, the company has broadened its technological offerings to include a variety of auto-injectors for subcutaneous and intramuscular administration, catering to specific patient and therapeutic requirements. At the core of Halozyme's innovation is its ENHANZE® drug delivery technology, which leverages the proprietary enzyme rHuPH20 to enhance the subcutaneous delivery of injectable drugs and fluids. This technology has been commercially validated and is notable for its potential to significantly improve patient experience by transforming lengthy IV infusions into quick subcutaneous injections. Through its focus on creating custom-designed drug delivery devices and its ENHANZE® platform, Halozyme aims to address and reduce the treatment burden for patients across various therapeutic areas.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
8374 M
Market cap (USD)
1,271,582
Daily traded volume (Shares)
48.63 / 47.65
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
